Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough

Cancer Communications

Table 1 EGFR-TKIs versus chemotherapy as second-line treatment for advanced NSCLC patients harboring wild-type EGFR mutations

Trial	Detection technique	Treatment	PFS (months)	HR for PFS (95% CI)	OS (months)	HR for OS (95% CI)	Reference
TAILOR	Sequencing	Erlotinib	2.4	0.71 (0.53–0.95)	5.4	0.73 (0.53–1.00)	[18]
TAILOR	Sequencing	Docetaxel	2.9	0.71 (0.53–0.95)	8.2	0.73 (0.53–1.00)	[18]
DELTA	PCR-based methods	Erlotinib	1.3	1.45 (1.09–1.94)	9.0	0.98 (0.69–1.39)	[19]
DELTA	PCR-based methods	Docetaxel	2.9	1.45 (1.09–1.94)	10.1	0.98 (0.69–1.39)	[19]
CTONG0806	DNA sequencing	Gefitinib	1.7	0.53 (0.38–0.75)	9.6	0.72 (0.49–1.04)	[20]
CTONG0806	ARMS	Pemetrexed	5.6	0.53 (0.38–0.75)	12.4	0.72 (0.49–1.04)	[20]

EGFR epidermal growth factor receptor, TKIs tyrosine kinase inhibitors, NSCLC non-small cell lung cancer, PCR polymerase chain reaction, ARMS Scorpion amplification refractory mutation system, PFS progression-free survival, HR hazard ratio, CI confidence interval, OS overall survival.

ISSN: 2523-3548